G
Grace Tyson
Researcher at University of Glasgow
Publications - 9
Citations - 198
Grace Tyson is an academic researcher from University of Glasgow. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 3, co-authored 4 publications receiving 31 citations.
Papers
More filters
Posted ContentDOI
Reduced neutralisation of the Delta (B.1.617.2) SARS-CoV-2 variant of concern following vaccination.
Chris Davis,Nicola S Logan,Grace Tyson,Richard J. Orton,William T. Harvey,Jonathan S Perkins,Guy Mollett,Rachel M Blacow,Thomas P. Peacock,Wendy S. Barclay,Peter Cherepanov,Massimo Palmarini,Pablo R. Murcia,Arvind H. Patel,David Robertson,John Haughney,E. Thomson,E. Thomson,Brian J. Willett +18 more
TL;DR: In this paper, the authors examined the sensitivity of variants of concern (VOCs) representative of the B.617.1, B.1.2 and B.351 lineages of SARS-CoV-2 to neutralization by sera from individuals vaccinated with the BNT162b2 (Pfizer/BioNTech) and ChAdOx1 (Oxford/AstraZeneca) vaccines.
Posted ContentDOI
Reduced neutralisation of the Delta (B.1.617.2) SARS-CoV-2 variant of concern following vaccination
Chris Davis,Nicola S Logan,Grace Tyson,Richard J. Orton,William T. Harvey,John Haughney,Jon Perkins,Thomas P. Peacock,Wendy S. Barclay,Peter Cherepanov,Massimo Palmarini,Pablo R. Murcia,Arvind H. Patel,David Robertson,E. Thomson,Brian J. Willett +15 more
TL;DR: In this paper, the authors examined the sensitivity of variants of concern (VOCs) representative of the B.617.1, B.1.2 and B.351 lineages of SARS-CoV-2 to neutralization by sera from individuals vaccinated with the BNT162b2 (Pfizer/BioNTech) and ChAdOx1 (Oxford/AstraZeneca) vaccines.
Journal ArticleDOI
Impaired neutralisation of SARS-CoV-2 delta variant in vaccinated patients with B cell chronic lymphocytic leukaemia
Helen Parry,Graham McIlroy,Rachel Bruton,Sarah Damery,Grace Tyson,Nicola S Logan,Chris Davis,Brian David Willett,Jianmin Zuo,Myah Ali,Manjit Kaur,Christine Stephens,Dawn Brant,Ashley Otter,Tina McSkeane,Hayley Rolfe,Sian E Faustini,Alex G. Richter,Sophie Lee,Farooq Wandroo,S. Shafeek,Guy Pratt,Shankara Paneesha,Paul Moss +23 more
TL;DR: In this article , the authors studied antibody responses in 500 patients following dual COVID-19 vaccination to assess the magnitude, correlates of response, stability and functional activity of the spike-specific antibody response with two different vaccine platforms.
Posted ContentDOI
Distinct antigenic properties of the SARS-CoV-2 Omicron lineages BA.4 and BA.5
Brian J. Willett,Ashwini Kurshan,Nazia Thakur,Joseph Newman,M. Manali,Grace Tyson,Nicola S Logan,Pablo R. Murcia,Luke B Snell,Jonathan D. Edgeworth,Jie Zhou,Ksenia Sukhova,Gayatri Amirthalingam,Kevin K. Brown,Bryan Charleston,Michael H. Malim,E. Thomson,Wendy S. Barclay,Dalan Bailey,Katie J. Doores,Thomas P. Peacock +20 more
TL;DR: The enhanced breadth of neutralisation observed following breakthrough infection with Omicron suggests that vaccination with heterologous or multivalent antigens may represent viable strategies for the development of cross-neutralising antibody responses.
Posted ContentDOI
Children develop strong and sustained cross-reactive immune responses against Spike protein following SARS-CoV-2 infection, with enhanced recognition of variants of concern
Alexander C Dowell,Megan S Butler,Elizabeth Jinks,Gokhan Tut,Tara Lancaster,Panagiota Sylla,Jusnara Begum,Rachel Bruton,Hayden Pearce,Kriti Verma,Nicola S Logan,Grace Tyson,Eliska Spalkova,Sandra Margielewska-Davies,Graham P. Taylor,Eleni Syrimi,Frances Baawuah,Joanne Beckmann,Ifeanyichukwu O Okike,Ifeanyichukwu O Okike,Shazaad Ahmad,Joanna Garstang,Andrew Brent,Bernadette Brent,Georgina Ireland,Felicity Aiano,Zahin Amin-Chowdhury,Samuel E. I. Jones,Ray Borrow,Ezra Linley,John Wright,Rafaq Azad,Dagmar Waiblinger,Chris Davis,E. Thomson,Massimo Palmarini,Brian J. Willett,Wendy S. Barclay,John Poh,Vanessa Saliba,Gayatri Amirthalingam,Kevin E. Brown,Mary Ramsay,Jianmin Zuo,Paul Moss,Shamez N Ladhani,Shamez N Ladhani +46 more
TL;DR: In this paper, the authors studied the profile of antibody and cellular immunity in children aged 3-11 years in comparison with adults and found that children were strong with high titres against spike protein and receptor binding domain (RBD).